Diabetes and obesity drug shows promise for fatty liver disease

Semaglutide, a GLP-1 agonist used to treat diabetes and obesity, may also help people with metabolic dysfunction–associated steatohepatitis, a severe stage of fatty liver disease, suggests a 2025 study.